Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation

The aim of the study was to assess the effect of transdermal testosterone on free testosterone concentrations in saliva and on short-term growth and bone turnover in boys with growth or pubertal delay. A prospective, randomized, crossover study was conducted over 26 wk with 4 wk of run-in, 8 wk of treatment I (8 or 12 h), 4 wk of washout, 8 wk of treatment II (8 or 12 h), and 4 wk of final washout. The main outcome measures were salivary testosterone profiles during the different study periods; weekly change in lower leg length (LLL) as measured by knemometry, i.e. LLL velocity; absolute and percentage change in bone alkaline phosphatase (bALP) levels; and deoxypyridinoline cross-links measured in urine. Eight boys who took part in the study had a median age of 13.5 yr (range, 12.4–14.9 yr), testicular volume of 3 ml (range, 2–6 ml), height sd score of −2.4 (range, −1.44 to −3.35), and bone age delay of 2 yr (range, 1–3.2 yr). Median salivary testosterone during 8- and 12-h treatments [179 pg/ml (range, 7–3579 pg/ml) and 150 pg/ml (range, 12–3472 pg/ml) (not significant)] was significantly higher than during the run-in and washout blocks (P < 0.0001) [9 pg/ml (range, <7 to 122 pg/ml) and 13 pg/ml (range, <7 to 285 pg/ml) (not significant)]. LLL velocity in the treatment blocks (median, 0.64 mm/wk; range, 0.1–1.08 mm/wk) was significantly higher than during the run-in and washout periods (median, 0.48 mm/wk; range, −0.06 to 0.92 mm/wk) (P < 0.001). The main rise in bALP occurred during the first treatment block with a median percentage change in bALP of 44.2% (range, −4 to 87%) and a smaller percentage change in bALP at the end of the second treatment block of 9.8% (range, −4 to 55%). The increases in bALP were not significantly different between the 8- and 12-h treatment periods, and there was no significant decline during the washout periods. Overnight transdermal testosterone application, as Virormone (5 mg), may be a potentially acceptable method of induction of puberty and stimulates short-term growth and bone turnover.

Download Full-text

Short-term complications after renal transplantation in AFibE526V (p.Glu545Val) amyloidosis

Amyloid ◽

10.1080/13506129.2019.1583196 ◽

2019 ◽

Vol 26 (sup1) ◽

pp. 162-163

Author(s):

Isabel Tavares ◽

José Silvano ◽

Luciana Moreira ◽

Márcia E. Oliveira ◽

Roberto Silva ◽

...

Keyword(s):

Renal Transplantation ◽

Short Term

Download Full-text

Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial

Osteoporosis International ◽

10.1007/s00198-011-1721-z ◽

2011 ◽

Vol 23 (3) ◽

pp. 1069-1074 ◽

Cited By ~ 23

Author(s):

S. L. Silverman ◽

K. Nasser ◽

S. Nattrass ◽

B. Drinkwater

Keyword(s):

Bone Turnover ◽

Bone Turnover Markers ◽

Community Setting ◽

Bisphosphonate Therapy ◽

Oral Bisphosphonate ◽

Turnover Markers ◽

Educational Information

Download Full-text

Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy

Journal of Clinical Oncology ◽

10.1200/jco.2007.15.1233 ◽

2008 ◽

Vol 26 (27) ◽

pp. 4426-4434 ◽

Cited By ~ 62

Author(s):

Susan L. Greenspan ◽

Joel B. Nelson ◽

Donald L. Trump ◽

Julie M. Wagner ◽

Megan E. Miller ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Density ◽

Bone Loss ◽

Bone Turnover ◽

Androgen Deprivation Therapy ◽

Bisphosphonate Therapy ◽

Androgen Deprivation ◽

Mineral Density ◽

Skeletal Health ◽

Oral Bisphosphonate

Purpose Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT. Patients and Methods A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers. Results Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% ± 0.7) and hip (mean, 1.3% ± 0.5%; both P < .01); those randomly assigned to placebo in year 2 maintained density at the spine and hip but lost (mean, −1.9% ± 0.6%; P < .01) at the forearm. Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone mass at the spine and hip, but experienced less of an increase compared with those who initiated alendronate at baseline. Men receiving alendronate for 2 years experienced a mean 6.7% (± 1.2%) increase at the spine and a 3.2% (± 1.5%) at the hip (both P < .05). Bone turnover remained suppressed. Conclusion Among men with nonmetastatic prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover. A second year of alendronate provides additional skeletal benefit, whereas discontinuation results in bone loss and increased bone turnover. Delay in bisphosphonate therapy appears detrimental to bone health.

Download Full-text